Psychotic symptoms are common in people with PD and are associated with poor prognosis, such as greater physical disability, cognitive and emotional impairment, caregiver distress, nursing home placement and death.
Eisai and Biogen have partnered to develop Leqembi and have priced it at $26,500 per year.
